A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This study is conducted to evaluate the safety and tolerability of the drug product sNN0031,
containing Platelet Derived Growth Factor (PDGF), when administered directly into one of the
fluid filled cavities in the brain using an implanted catheter and an implanted SynchroMed®
II pump. Patients with a diagnosis of Parkinson's disease will be enrolled.